Latest issue 30 Oct 2026

CRC Research Update — October 30, 2026

Today's colorectal cancer research highlights

2 min read

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

Signal Key

TRIAL DATA clinical trial results, efficacy data, survival endpoints TREATMENT new treatment options, regimen changes, combination therapies REGULATORY FDA/EMA approvals, guideline updates, NCCN/ESMO changes RESEARCH cancer biology, biomarker discoveries, resistance pathways SCREENING screening, colonoscopy guidelines, liquid biopsy, molecular profiling LIVING WITH CRC survivorship, quality of life, side effects, patient decision-making, caregiver support

CRC Research Update

RESEARCH
Single-cell atlas reveals early-onset colorectal cancer has more stroma, less tumor epithelium
Analysis of 189 tumors spanning eight decades found that microsatellite-stable tumors from younger patients had increased stromal and decreased epithelial proportions, with epithelial cells showing higher expression of long noncoding RNAs and FN1. (Nature Medicine)
TRIAL DATA
BRAF-directed therapy outperforms EGFR inhibition in metastatic BRAF-mutant CRC
Meta-analysis of 18 randomized trials (11,931 participants) found pooled median overall survival of 22.3 months for BRAF-directed regimens versus 10.1 months for EGFR-directed therapy in first-line treatment. (Journal of Gastrointestinal Cancer)
RESEARCH
PIK3C3 inhibition enhances 5-FU sensitivity in KRAS-mutant cells, opposite effect in KRAS-wild-type
Laboratory study found PIK3C3 knockdown increased 5-fluorouracil resistance in KRAS-wild-type cells but enhanced sensitivity in KRAS-mutant cells, potentially through thymidylate synthase regulation. (Cancer Medicine)
SCREENING
Dual-gene stool DNA test achieves 82.9% sensitivity for colorectal cancer detection
Cross-sectional study of 274 participants found combined SDC2 and ADHFE1 methylation analysis in stool samples detected colorectal cancer with 82.9% sensitivity and an AUC of 0.865, though discrimination of advanced adenoma from healthy controls remained limited. (BMC Gastroenterology)

🔬 Under 50 Spotlight

Research relevant to early-onset and younger CRC patients

Obesity reshapes gut microbiota and drives early-onset CRC through dysbiosis and inflammation
Narrative review explores how diet-induced adiposity depletes protective bacteria, enriches genotoxic pathobionts, and promotes systemic inflammation that creates a fertile niche for early-onset carcinogenesis. (In Vivo)

🧬 Biomarker Spotlight

Research by genetic subtype. KRAS, BRAF, MSI-H, HER2, and more

New predictive model identifies mismatch repair deficiency in resource-limited settings
Cross-sectional analysis of 185 Sri Lankan patients found 12.4% were mismatch repair deficient; multivariable analysis identified age under 60, right-sided tumors, family history, and specific histologic features as significant predictors. (BMC Cancer)

This week's research spans molecular profiling of early-onset disease, biomarker-guided therapy selection, and non-invasive detection strategies.

Get CRC research intelligence delivered weekly, free.

Browse by Topic

KRAS Mutations Immunotherapy (MSI-H)BRAF Early-Onset / Under 50 Liver Metastases Clinical Trials Living with CRC All Issues

CRC Research Update

Subscribe to The CRC Digest